

Diagnosis and management of resistant hypertension: s

Nature Reviews Nephrology

14, 428-441

DOI: [10.1038/s41581-018-0006-6](https://doi.org/10.1038/s41581-018-0006-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Diagnosis and Management of Resistant Hypertension. Hypertension, 2019, 74, 1064-1067.	1.3	1
2	Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. Frontiers in Pharmacology, 2019, 10, 1231.	1.6	0
3	Resistant Hypertension. Endocrinology and Metabolism Clinics of North America, 2019, 48, 811-828.	1.2	5
4	Editorial: Endocrine Forms of Hypertension: Clinical and Emerging Molecular Aspects. Frontiers in Endocrinology, 2019, 10, 857.	1.5	0
5	Management of resistant hypertension. Current Opinion in Cardiology, 2019, 34, 367-375.	0.8	2
6	Resistant and refractory hypertension: two sides of the same disease?. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 266-274.	0.4	11
7	Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms. Hypertension, 2019, 73, 250-257.	1.3	15
8	Resistant Hypertension: Novel Insights. Current Hypertension Reviews, 2020, 16, 61-72.	0.5	41
9	2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, 75, 1334-1357.	1.3	1,895
10	2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 2020, 38, 982-1004.	0.3	452
11	Association of the genetic ancestry with resistant hypertension in the ReHOT (Resistant Hypertension) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	3
12	Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. Cancer Research, 2021, 81, 2086-2100.	0.4	8
13	Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension, 2021, 77, 788-798.	1.3	7
14	Assessment of a strategy combining ambulatory blood pressure, adherence monitoring and a standardised triple therapy in resistant hypertension. Blood Pressure, 2021, 30, 332-340.	0.7	1
15	First look at new 2018 joint ESH/ESC Guidelines on diagnosis and management of hypertension. Arterial Hypertension (Russian Federation), 2018, 24, 351-358.	0.1	15
16	Medication Adherence and Treatment-Resistant Hypertension in Newly Treated Hypertensive Patients in the United Arab Emirates. Journal of Clinical Medicine, 2021, 10, 5036.	1.0	7
18	Interventional Therapy in Refractory Hypertension: An Update. Revista Romana De Cardiologie, 2022, 32, 79-84.	0.0	0
19	Role of home blood pressure monitoring in resistant hypertension. Clinical Hypertension, 2023, 29, .	0.7	5

#	ARTICLE	IF	CITATIONS
20	Regulatory effect of dietary nitrate on blood pressure: a meta-analysis of randomized controlled trials. Food and Function, 2023, 14, 1839-1850.	2.1	2
21	THE ALGORITHM FOR THE TREATMENT OF PATIENTS WITH TREATMENT-RESISTANT HYPERTENSION AT THE OUTPATIENT STAGE. Modern Medical Technologies, 2023, , 69-73.	0.1	0
23	A review on nano-formulation of calcium channel inhibitors in treatment of hypertension. AIP Conference Proceedings, 2023, , .	0.3	0
24	Isolated Systolic Hypertension. , 2024, , 220-228.		0